Media Coverage · July 4, 2018
Acticor Biotech retient Simbec-Orion pour une étude clinique – Actulabo [FR]
July 2018. La biopharm française Acticor Biotech (traitement des phases aiguës des maladies thrombotiques) a confié à la CRO Simbec-Orion la réalisation d’une étude de phase II portant sur l’ACT017 …
Download full text article (PDF, French)
Read next in 'Media Coverage'
- Novel antiplatelet could circumvent bleeding risk for stroke patients
- Experimental antiplatelet compound for acute stroke shows promise
- New drug to prevent clots clears safety hurdle
- New blood thinner may prevent stroke, without risk for bleeding
- Acticor's blood thinner cuts hemorrhage risk in human study, could offer hope for acute stroke